Synergy against extensively drug-resistant Acinetobacter baumannii in vitro by two old antibiotics: colistin and chloramphenicol

被引:28
|
作者
Wei, Wen-juan [1 ]
Yang, Hai-fei [2 ,3 ,4 ]
机构
[1] Southeast Univ, Sch Med, Dept Microbiol & Immunol, Nanjing, Jiangsu, Peoples R China
[2] Soochow Univ, Affiliated Hosp 1, Dept Hematol, Suzhou, Peoples R China
[3] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Suzhou, Peoples R China
[4] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Dept Hematol, Shizi St 188, Suzhou 215006, Peoples R China
关键词
Colistin; Chloramphenicol; Antimicrobial synergy; Acinetobacter baumannii; GALLERIA-MELLONELLA MODEL; PSEUDOMONAS-AERUGINOSA; VIVO ACTIVITY; COMBINATION; INFECTION; THERAPY;
D O I
10.1016/j.ijantimicag.2016.11.031
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Combination antimicrobial therapy is an important option in the fight against Gram-negative 'superbugs'. This study systematically investigated the synergistic effect of colistin (CST) and chloramphenicol (CHL) in combination against extensively drug-resistant Acinetobacter baumannii (XDR-AB). The microtitre plate chequerboard assay was used to test synergy against 50 XDR-AB clinical strains. Then, three XDR-AB clinical isolates and the type strain A. baumannii ATCC 19606 were chosen for further synergy studies using time-kill assay, mutant prevention concentration (MPC) assay and real-time population analysis profile (PAP) assay. In the chequerboard assays, synergistic or additive effects [defined as a fractional inhibitory concentration index (FICI) of <= 0.5 and 0.5 < FICI < 1, respectively] were observed in all 50 isolates. In further synergy testing, the results of time-kill assays indicated that CST monotherapy produced rapid bacterial killing followed by rapid re-growth, with the emergence of CST resistance; CHL monotherapy was largely ineffective. The combination CST/CHL, however, showed a synergistic effect and enhanced bacterial killing in the four tested strains. It also significantly delayed re-growth and suppressed the emergence of CST resistance. In the MPC assay, a decrease in MPCs for CST was observed in the two CSTsusceptible strains. PAP assay showed that both CST-resistant strains were heteroresistant. (C) 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:321 / 326
页数:6
相关论文
共 50 条
  • [1] In vitro synergy of colistin combinations against extensively drug-resistant Acinetobacter baumannii producing OXA-23 carbapenemase
    Wei, Wenjuan
    Yang, Haifei
    Liu, Yanyan
    Ye, Ying
    Li, Jiabin
    JOURNAL OF CHEMOTHERAPY, 2016, 28 (03) : 159 - 163
  • [2] In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii
    Park, Gyun Cheol
    Choi, Ji Ae
    Jang, Sook Jin
    Jeong, Seok Hoon
    Kim, Choon-Mee
    Choi, In Sun
    Kang, Seong Ho
    Park, Geon
    Moon, Dae Soo
    ANNALS OF LABORATORY MEDICINE, 2016, 36 (02) : 124 - 130
  • [3] In Vitro Activities of Novel Antimicrobial Combinations against Extensively Drug-Resistant Acinetobacter baumannii
    Cordoba, J.
    Coronado-Alvarez, N. M.
    Parra, D.
    Parra-Ruiz, J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (12) : 7316 - 7319
  • [4] Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia
    Khawcharoenporn, Thana
    Pruetpongpun, Nattapol
    Tiamsak, Pimsiri
    Rutchanawech, Sasinuch
    Mundy, Linda M.
    Apisarnthanarak, Anucha
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2014, 43 (04) : 378 - 382
  • [5] Rifampicin Plus Colistin in the Era of Extensively Drug-Resistant Acinetobacter baumannii Infections
    Gauthier, Timothy P.
    CLINICAL INFECTIOUS DISEASES, 2013, 57 (03) : 359 - 361
  • [6] Extensively Drug-Resistant Acinetobacter baumannii
    Doi, Yohei
    Husain, Shahid
    Potoski, Brian A.
    McCurry, Kenneth R.
    Paterson, David L.
    EMERGING INFECTIOUS DISEASES, 2009, 15 (06) : 980 - 982
  • [7] Predictors of mortality in patients with extensively drug-resistant Acinetobacter baumannii pneumonia receiving colistin therapy
    Choi, Ik Sung
    Lee, Yu Ji
    Wi, Yu Mi
    Kwan, Byung Soo
    Jung, Kae Hwa
    Hong, Woong Pyo
    Kim, June Myong
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2016, 48 (02) : 175 - 180
  • [8] In vitro activities of sitafloxacin tested alone and in combination with rifampin, colistin, sulbactam, and tigecycline against extensively drug-resistant Acinetobacter baumannii
    Dong, Xiaomeng
    Chen, Fengzhe
    Zhang, Yajun
    Liu, Haihong
    Liu, Yongjuan
    Ma, Lixian
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (05): : 8135 - 8140
  • [9] Dissecting Colistin Resistance Mechanisms in Extensively Drug-Resistant Acinetobacter baumannii Clinical Isolates
    Trebosc, Vincent
    Gartenmann, Sarah
    Totzl, Marcus
    Lucchini, Valentina
    Schellhorn, Birgit
    Pieren, Michel
    Lociuro, Sergio
    Gitzinger, Marc
    Tigges, Marcel
    Bumann, Dirk
    Kemmer, Christian
    MBIO, 2019, 10 (04):
  • [10] In vitro activities of rifampin, colistin, sulbactam and tigecycline tested alone and in combination against extensively drug-resistant Acinetobacter baumannii
    Dong, Xiaomeng
    Chen, Fengzhe
    Zhang, Yajun
    Liu, Haihong
    Liu, Yongjuan
    Ma, Lixian
    JOURNAL OF ANTIBIOTICS, 2014, 67 (09) : 677 - 680